Project Grant R44HL149579

This $568,264 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The goal is to create a renewable source of RBCs with unique Rh profiles to facilitate the identification of complex Rh antibodies, which is critical for selecting compatible blood donors and...

This three-year, $1.977 million Project Grant from the Department of the Army Medical Command will support Cytosorbents Medical Inc.'s demonstration of the safety and efficacy of its field-ready blood group antibody (BGA) adsorber in a porcine universal transfusion model. The Military Medical Research and Development program (CFDA 12.420) aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine. Under this award, Cytosorbents...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $715,110 to The Pennsylvania State University to conduct research on a novel blood substitute prototype called "nano-RBC" or "Nano-RBC." The goal is to develop a deformable, toroidal-shaped nanoparticle that can serve as an artificial oxygen carrier to substitute for banked blood. The research focuses on optimizing the...

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $175,000 cooperative agreement to Blood Centers of America, Inc. to determine the feasibility of establishing a strategic stockpile of blood donation supplies. This award falls under the Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion program (CFDA 93.078), which aims to strengthen emergency care systems and...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Covenant Therapeutics LLC a $249,965 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) on September 10, 2023. The purpose of this grant is to further develop a novel therapeutic approach involving small peptide erythropoietin (EPO) analogs as an alternative to recombinant human EPO for the treatment of anemias, particularly those secondary to renal disease and malignancy. The key objectives are to optimize the lead...

This federal Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $940,821 to Cryocrate LLC, a for-profit biotech company based in Columbia, Missouri, to develop a first-in-class biocompatible and efficient cryopreservation technology platform for cell-based therapeutics in regenerative medicine and drug discovery. The key objectives of this project are: (I) Producing the company's proprietary Odinsol cryopreservation medium...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), with a total funding amount of $392,660, supports research to investigate the role of red blood cells and the toll-like receptor 7 (TLR7) in regulating the immune response during sepsis. The project, titled "Investigating the Function of RBC-TLR7 in Sepsis," aims to elucidate novel mechanisms of immune dysregulation in sepsis and enhance the understanding of how red blood cells contribute to the...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $265,347 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Functional Fluidics Inc., a minority-owned for-profit company in Detroit, Michigan. The grant supports the development and initial validation of a point-of-care (POC) device to assess red blood cell (RBC) sickling as an indicator of sickle cell disease (SCD) patient condition and treatment monitoring. The proposed "Dynamic Sickling...

This $677,600 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to gain a mechanistic understanding of erythroid progenitor (EP) self-renewal, both in vitro and in vivo. The primary goals are to: Test the hypothesis that the BMI1/RING1B chromatin modulators regulate human self-renewing erythroblast (SRE) self-renewal through epigenetic control of transcription and cholesterol homeostasis. Test the hypothesis that...

This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,011,109.00 to Cryocrate LLC, a for-profit limited liability company based in Columbia, Missouri, to develop and secure FDA clearance for their novel cryopreservation technology, Odinsol. The key objectives are to establish GMP production capabilities and conduct in vitro and in vivo evaluations to demonstrate the biocompatibility and...